The American Journal of Surgery
Volume 186, Issue 4 , Pages 351-358, October 2003

The molecular detection of micrometastatic breast cancer

Presented at the Fourth Annual Meeting of the American Society of Breast Surgeons, Atlanta, Georgia, April 30–May 4, 2003.

  • Megan Baker, M.D.

      Affiliations

    • Medical University of South Carolina, Department of Surgery, 171 Ashley Ave., Room 420Q CSB, Charleston, SC 29425, USA
  • ,
  • William E Gillanders, M.D.

      Affiliations

    • Medical University of South Carolina, Department of Surgery, 171 Ashley Ave., Room 420Q CSB, Charleston, SC 29425, USA
  • ,
  • Kaidi Mikhitarian, M.D.

      Affiliations

    • Medical University of South Carolina, Department of Surgery, 171 Ashley Ave., Room 420Q CSB, Charleston, SC 29425, USA
  • ,
  • Michael Mitas, Ph.D.

      Affiliations

    • Medical University of South Carolina, Department of Surgery, 171 Ashley Ave., Room 420Q CSB, Charleston, SC 29425, USA
  • ,
  • David J Cole, M.D.

      Affiliations

    • Medical University of South Carolina, Department of Surgery, 171 Ashley Ave., Room 420Q CSB, Charleston, SC 29425, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-843-792-4638; fax: +1-843-792-3315.

Received 3 June 2003; received in revised form 21 June 2003

Abstract 

Background

The rapid evolution of molecular technology and novel markers provides the opportunity to establish a more effective means to detect micrometastatic breast cancer. Given the controversies concerning application and clinical relevance, this review critically evaluates the current status of these molecular staging technologies.

Data sources

Breast cancer literature addressing (1) molecular detection methodologies (immunohistochemistry, reverse transcriptase polymerase chain reaction, and microarray analysis); (2) specific tissue applications such as lymph nodes, bone marrow aspirate, and peripheral blood; (3) expert commentary concerning the clinical applications and pitfalls of these technologies; and (4) recent data from our molecular diagnostics laboratory.

Conclusions

Molecular detection technologies such as reverse transcriptase polymerase chain reaction and microarray analyses are being developed that will likely have future application as cancer diagnostics. Further work is needed to establish assays that are validated by prospective clinical studies. Early identification of clinically relevant disease could lead to new treatment or staging approaches for breast cancer.

Keywords:  Breast cancer, Micrometastases, Polymerase chain reaction, Immunohistochemistry, Sentinel lymph node, Peripheral blood

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9610(03)00262-9

doi:10.1016/S0002-9610(03)00262-9

The American Journal of Surgery
Volume 186, Issue 4 , Pages 351-358, October 2003